热门资讯> 正文

Fully Therapeutics GAAP每股收益为-0.31美元在线

2026-02-24 20:20

Fulcrum Therapeutics(FULC) 0

Fulcrum Therapeutics press release (FULC): Q4 GAAP EPS of -$0.31 in-line.
Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029.
Based on its current operating plans, Fulcrum now expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund its operating requirements into 2029.

More on Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock
Seeking Alpha’s Quant Rating on Fulcrum Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。